Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Nielen, M. M. J., van Schaardenburg, D., Reesink, H. W., van de Stadt, R. J., van der Horst‐Bruinsma, I. E., de Koning, M. H. M. T., Habibuw, M. R., Vandenbroucke, J. P., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20018 · Cited by 1,861
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
THE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
Daneman, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68341-4 · Cited by 921
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
Mayer-Davis, E. J., Kahkoska, A. R., Jefferies, C., Dabelea, D., Balde, N., Gong, C. X., Aschner, P., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12773 · Cited by 682
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Autoimmune Polyendocrine Syndromes
Eisenbarth, G. S., & Gottlieb, P. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030158 · Cited by 672
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Arif, S., Tree, T. I., Astill, T. P., Tremble, J. M., Bishop, A. J., Dayan, C. M., Roep, B. O., & Peakman, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19585 · Cited by 479
The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure
Roep, B. O. (2003) · Diabetologia · doi:10.1007/s00125-003-1089-5 · Cited by 431
Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Misso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
Definition, epidemiology, and classification of diabetes in children and adolescents
Craig, M. E., Jefferies, C., Dabelea, D., Balde, N., Seth, A., & Donaghue, K. C. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12186 · Cited by 366
Type 1 diabetes: pathogenesis and prevention
Gillespie, K. M. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060244 · Cited by 387
Näntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340
Alternative routes of insulin delivery
Owens, D. R., Zinman, B., & Bolli, G. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01076.x · Cited by 332
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents
Dunger, D. B. (2004) · Archives of Disease in Childhood · doi:10.1136/adc.2003.044875 · Cited by 321
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
Shoda, L. K. M., Young, D. L., Ramanujan, S., Whiting, C. C., Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Mathis, D., Rossini, A. A., Campbell, S. E., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.08.002 · Cited by 317
Pihoker, C., Gilliam, L. K., Hampe, C. S., & Lernmark, A. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s52 · Cited by 303
The Environmental Determinants of Diabetes in the Young (TEDDY) Study
TEDDY Study Group (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.062 · Cited by 306
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Dunger, D. B., Sperling, M. A., Acerini, C. L., Bohn, D. J., Daneman, D., Danne, T. P. A., Glaser, N. S., Hanas, R., Hintz, R. L., Levitsky, L. L., et al. (2004) · Pediatrics · doi:10.1542/peds.113.2.e133 · Cited by 296
Clinical Applications of Diabetes Antibody Testing
Bingley, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1365 · Cited by 278
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Littorin, B., Blom, P., Schölin, A., Arnqvist, H. J., Blohmé, G., Bolinder, J., Ekbom-Schnell, A., Eriksson, J. W., Gudbjörnsdottir, S., Nyström, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0426-x · Cited by 276
100 years of insulin: celebrating the past, present and future of diabetes therapy
Sims, E. K., Carr, A. L. J., Oram, R. A., DiMeglio, L. A., & Evans-Molina, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01418-2 · Cited by 270
Type 1 diabetes as a relapsing–remitting disease?
von Herrath, M., Sanda, S., & Herold, K. (2007) · Nature Reviews Immunology · doi:10.1038/nri2192 · Cited by 270
Quattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 244
Orban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges
Holmgren, J., Czerkinsky, C., Eriksson, K., & Mharandi, A. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00206-8 · Cited by 260
Latent Autoimmune Diabetes in Adults
Naik, R. G., Brooks-Worrell, B. M., & Palmer, J. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1120 · Cited by 249
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 237
Antigen-specific therapeutic approaches for autoimmunity
Serra, P., & Santamaria, P. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0015-4 · Cited by 228
The immunology of type 1 diabetes
Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. K. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00985-4 · Cited by 212
Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
von Boehmer, H., & Daniel, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 220
Barker, J. M., Goehrig, S. H., Barriga, K., Hoffman, M., Slover, R., Eisenbarth, G. S., Norris, J. M., Klingensmith, G. J., & Rewers, M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1399 · Cited by 220
Redondo, M. J., Steck, A. K., & Pugliese, A. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12597 · Cited by 216
Rat Models of Type 1 Diabetes: Genetics, Environment, and Autoimmunity
Mordes, J. P., Bortell, R., Blankenhorn, E. P., Rossini, A. A., & Greiner, D. L. (2004) · ILAR Journal · doi:10.1093/ilar.45.3.278 · Cited by 218
Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S., & Greenbaum, C. J. (2017) · JAMA · doi:10.1001/jama.2017.17070 · Cited by 214
Latent Autoimmune Diabetes in Adults
Stenström, G., Gottsäter, A., Bakhtadze, E., Berger, B., & Sundkvist, G. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s68 · Cited by 213
Type 1 diabetes mellitus: etiology, presentation, and management
Haller, M. J., Atkinson, M. A., & Schatz, D. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.006 · Cited by 211
Extrapancreatic insulin-producing cells in multiple organs in diabetes
Kojima, H., Fujimiya, M., Matsumura, K., Nakahara, T., Hara, M., & Chan, L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308690100 · Cited by 211
Immunological Responses to Exogenous Insulin
Fineberg, S. E., Kawabata, T. T., Finco-Kent, D., Fountaine, R. J., Finch, G. L., & Krasner, A. S. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0002 · Cited by 209
Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes
Roep, B. O., Atkinson, M., & von Herrath, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1502 · Cited by 212
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2017) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2017/6949835 · Cited by 194
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Update on cystic fibrosis-related diabetes
Kelly, A., & Moran, A. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.02.008 · Cited by 203
Mahon, J. L., Sosenko, J. M., Rafkin-Mervis, L., Krause-Steinrauf, H., Lachin, J. M., Thompson, C., Bingley, P. J., Bonifacio, E., Palmer, J. P., Eisenbarth, G. S., et al. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00464.x · Cited by 201
Bonifacio, E., Ziegler, A.-G., Klingensmith, G., Schober, E., Bingley, P. J., Rottenkolber, M., Theil, A., Eugster, A., Puff, R., Peplow, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.2928 · Cited by 196
HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms
Thorsby, E., & Lie, B. A. (2005) · Transplant Immunology · doi:10.1016/j.trim.2005.03.021 · Cited by 196
Engineering antigens for in situ erythrocyte binding induces T-cell deletion
Kontos, S., Kourtis, I. C., Dane, K. Y., & Hubbell, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216353110 · Cited by 190
Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes
Michels, A. W., Landry, L. G., McDaniel, K. A., Yu, L., Campbell-Thompson, M., Kwok, W. W., Jones, K. L., Gottlieb, P. A., Kappler, J. W., Tang, Q., et al. (2017) · Diabetes · doi:10.2337/db16-1025 · Cited by 190
Overcoming barriers to early disease intervention
Caicedo, H. H., Hashimoto, D. A., Caicedo, J. C., Pentland, A., & Pisano, G. P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0550-z · Cited by 182
Driver, J. P., Serreze, D. V., & Chen, Y.-G. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0204-1 · Cited by 178
Bos, W. H., Dijkmans, B. A. C., Boers, M., van de Stadt, R. J., & van Schaardenburg, D. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105767 · Cited by 174
Kavvoura, F. K., & Ioannidis, J. P. A. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi165 · Cited by 173
Natural History of β-Cell Function in Type 1 Diabetes
Sherry, N. A., Tsai, E. B., & Herold, K. C. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s32 · Cited by 168
Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice
Koulmanda, M., Bhasin, M., Hoffman, L., Fan, Z., Qipo, A., Shi, H., Bonner-Weir, S., Putheti, P., Degauque, N., Libermann, T. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808031105 · Cited by 165
Altered Natural Killer Cells in Type 1 Diabetic Patients
Rodacki, M., Svoren, B., Butty, V., Besse, W., Laffel, L., Benoist, C., & Mathis, D. (2007) · Diabetes · doi:10.2337/db06-0493 · Cited by 163
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 205
Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
Sosenko, J. M., Palmer, J. P., Greenbaum, C. J., Mahon, J., Cowie, C., Krischer, J. P., Chase, H. P., White, N. H., Buckingham, B., Herold, K. C., et al. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1006 · Cited by 157
Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study
Thrower, S. L., James, L., Hall, W., Green, K. M., Arif, S., Allen, J. S., Van-Krinks, C., Lozanoska-Ochser, B., Marquesini, L., Brown, S., et al. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03814.x · Cited by 153
Besser, R. E. J., Bell, K. J., Couper, J., Ziegler, A., Wherrett, D. K., Knip, M., Speake, C., Casteels, K., Driscoll, K. A., Jacobsen, L. M., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13410 · Cited by 188
Diabetes as a Determinant of Mortality in Cystic Fibrosis
Chamnan, P., Shine, B. S. F., Haworth, C. S., Bilton, D., & Adler, A. I. (2010) · Diabetes Care · doi:10.2337/dc09-1215 · Cited by 151
Insulin Intervention in Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus
Maruyama, T., Tanaka, S., Shimada, A., Funae, O., Kasuga, A., Kanatsuka, A., Takei, I., Yamada, S., Harii, N., Shimura, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2267 · Cited by 146
Couper, J., Haller, M. J., Greenbaum, C. J., Ziegler, A., Wherrett, D. K., Knip, M., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12734 · Cited by 172
Apoptotic signal transduction pathways in diabetes
Mandrup-Poulsen, T. R. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00494-5 · Cited by 161
Autoimmune Markers in Diabetes
Winter, W. E., & Schatz, D. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.148205 · Cited by 158
Han, B., Serra, P., Amrani, A., Yamanouchi, J., Marée, A. F. M., Edelstein‐Keshet, L., & Santamaría, P. (2005) · Nature Medicine · doi:10.1038/nm1250 · Cited by 142
Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
Ferrannini, E., Mari, A., Nofrate, V., Sosenko, J. M., Skyler, J. S., & for the DPT-1 Study Group (2010) · Diabetes · doi:10.2337/db09-1378 · Cited by 140
Staeva-Vieira, T., Peakman, M., & Von Herrath, M. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03328.x · Cited by 138
Annoni, A., Brown, B. D., Cantore, A., Sergi, L. S., Naldini, L., & Roncarolo, M.-G. (2009) · Blood · doi:10.1182/blood-2009-04-214569 · Cited by 134
Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Luo, X., Herold, K. C., & Miller, S. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.002 · Cited by 136
Chen, Y.-G., Mathews, C. E., & Driver, J. P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00051 · Cited by 134
Aumeunier, A., Grela, F., Ramadan, A., Pham Van, L., Bardel, E., Gomez Alcala, A., Jeannin, P., Akira, S., Bach, J.-F., & Thieblemont, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011484 · Cited by 132
Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes
Jaeckel, E., Lipes, M. A., & von Boehmer, H. (2004) · Nature Immunology · doi:10.1038/ni1120 · Cited by 133
Immune modulation in humans: implications for type 1 diabetes mellitus
Roep, B. O., & Tree, T. I. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.2 · Cited by 139
Coco, G., Dal Pra, C., Presotto, F., Albergoni, M. P., Canova, C., Pedini, B., Zanchetta, R., Chen, S., Furmaniak, J., Rees Smith, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0860 · Cited by 127
The stages of type 1A diabetes: 2005
Gianani, R., & Eisenbarth, G. S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00248.x · Cited by 127
Pivonello, R., De Bellis, A., Faggiano, A., Di Salle, F., Petretta, M., Di Somma, C., Perrino, S., Altucci, P., Bizzarro, A., Bellastella, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020791 · Cited by 127
Karlson, E. W., Chibnik, L. B., Tworoger, S. S., Lee, I., Buring, J. E., Shadick, N. A., Manson, J. E., & Costenbader, K. H. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24350 · Cited by 127
Orban, T., Farkas, K., Jalahej, H., Kis, J. T., Treszl, A., Falk, B. A., Reijonen, H., Wolfsdorf, J. I., Ricker, A. T., Matthews, J. B., et al. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.10.005 · Cited by 128
Type 1 diabetes vaccine candidates promote human Foxp3+Treg induction in humanized mice
Serr, I., Fürst, R. W., Achenbach, P., Scherm, M. G., Gökmen, F., Haupt, F., Sedlmeier, E.-M., Knopff, A., Shultz, L., Willis, R. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms10991 · Cited by 123
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.